Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma is a very rare variant of diffuse large B-cell lymphoma (DLBCL) mainly affecting middle-aged immunocompetent men and characterized by a consistent primary involvement of lymph nodes (mainly in the cervical and mediastinum lymph nodes) and with infrequent extra nodal involvement of the bone marrow and other extra-nodal sites (head and neck region, liver, spleen, and gastrointestinal tract). It has an aggressive disease course, and is associated with a poor prognosis.
4 clinical trials registered, 2 recruiting. Interventions under study include drug therapy, biologic therapy, and procedural interventions. Pipeline includes 2 PHASE2, 2 PHASE1. Research is sponsored by a mix of industry and academic institutions.
14 publications have been identified in PubMed for ALK-positive large B-cell lymphoma. Research spans Case Report / Case Series (50%), Review / Meta-Analysis (21%), and Basic Science / Preclinical (14%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 7 |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 7:55 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about ALK-positive large B-cell lymphoma
50%
Research summaries | 3 | 21% |
Laboratory research | 2 | 14% |
Clinical study results | 1 | 7% |
Disease patterns and progression | 1 | 7% |
Dananjaya R (2026). [PMID: 41798535](https://pubmed.ncbi.nlm.nih.gov/41798535/). *Cureus*. [Case Report / Case Series]
Castillo JJ (2026). [PMID: 42138287](https://pubmed.ncbi.nlm.nih.gov/42138287/). *Am J Hematol*. [Review / Meta-Analysis]
Surintrspanont CP (2026). [PMID: 41806055](https://pubmed.ncbi.nlm.nih.gov/41806055/). *J Hematop*. [Case Report / Case Series]
Atallah-Yunes SA (2025). [PMID: 40899786](https://pubmed.ncbi.nlm.nih.gov/40899786/). *Am J Hematol*. [Clinical Trial Publication]
Verma A (2025). [PMID: 39780422](https://pubmed.ncbi.nlm.nih.gov/39780422/). *Indian J Pathol Microbiol*. [Epidemiology / Natural History]
Wang WJ (2025). [PMID: 40423499](https://pubmed.ncbi.nlm.nih.gov/40423499/). *Am J Hematol*. [Case Report / Case Series]
Zanelli M (2025). [PMID: 40869163](https://pubmed.ncbi.nlm.nih.gov/40869163/). *Int J Mol Sci*. [Review / Meta-Analysis]
Glaser S (2025). [PMID: 40879321](https://pubmed.ncbi.nlm.nih.gov/40879321/). *Genes Chromosomes Cancer*. [Basic Science / Preclinical]
Singh S (2025). [PMID: 41277596](https://pubmed.ncbi.nlm.nih.gov/41277596/). *Turk Patoloji Derg*. [Case Report / Case Series]
Wang H (2024). [PMID: 39906668](https://pubmed.ncbi.nlm.nih.gov/39906668/). *Front Oncol*. [Case Report / Case Series]